139 related articles for article (PubMed ID: 30240830)
1. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid.
Borghoff SJ; Fitch S; Rager JE; Huggett D
Regul Toxicol Pharmacol; 2018 Nov; 99():168-181. PubMed ID: 30240830
[TBL] [Abstract][Full Text] [Related]
2. Hypothesis-driven weight of evidence analysis to determine potential endocrine activity of MTBE.
de Peyster A; Mihaich E
Regul Toxicol Pharmacol; 2014 Aug; 69(3):348-70. PubMed ID: 24813373
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
[TBL] [Abstract][Full Text] [Related]
4. Perfluorohexanoic acid toxicity, part I: Development of a chronic human health toxicity value for use in risk assessment.
Luz AL; Anderson JK; Goodrum P; Durda J
Regul Toxicol Pharmacol; 2019 Apr; 103():41-55. PubMed ID: 30639337
[TBL] [Abstract][Full Text] [Related]
5. Weight-of-the-evidence evaluation of 2,4-D potential for interactions with the estrogen, androgen and thyroid pathways and steroidogenesis.
Neal BH; Bus J; Marty MS; Coady K; Williams A; Staveley J; Lamb JC
Crit Rev Toxicol; 2017 May; 47(5):345-401. PubMed ID: 28303741
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the toxicity mechanisms of perfluorohexanoic acid (PFHxA) and perfluorohexanesulphonic acid (PFHxS) in fish.
Kreychman M; Ivantsova E; Lu A; Bisesi JH; Martyniuk CJ
Comp Biochem Physiol C Toxicol Pharmacol; 2024 May; 279():109874. PubMed ID: 38423199
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the chronic toxicity and carcinogenicity of perfluorohexanoic acid (PFHxA) in Sprague-Dawley rats.
Klaunig JE; Shinohara M; Iwai H; Chengelis CP; Kirkpatrick JB; Wang Z; Bruner RH
Toxicol Pathol; 2015 Feb; 43(2):209-20. PubMed ID: 25377447
[TBL] [Abstract][Full Text] [Related]
8. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
[TBL] [Abstract][Full Text] [Related]
9. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
[TBL] [Abstract][Full Text] [Related]
10. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis-driven weight-of-evidence analysis for the endocrine disruption potential of benzene.
Mihaich EM; Borgert CJ
Regul Toxicol Pharmacol; 2018 Dec; 100():7-15. PubMed ID: 30273620
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional changes in steroidogenesis by perfluoroalkyl acids (PFOA and PFOS) regulate the synthesis of sex hormones in H295R cells.
Kang JS; Choi JS; Park JW
Chemosphere; 2016 Jul; 155():436-443. PubMed ID: 27139122
[TBL] [Abstract][Full Text] [Related]
13. Perfluorohexanoic acid toxicity, part II: Application of human health toxicity value for risk characterization.
Anderson JK; Luz AL; Goodrum P; Durda J
Regul Toxicol Pharmacol; 2019 Apr; 103():10-20. PubMed ID: 30634020
[TBL] [Abstract][Full Text] [Related]
14. Perfluorooctane sulfonate (PFOS) affects hormone receptor activity, steroidogenesis, and expression of endocrine-related genes in vitro and in vivo.
Du G; Hu J; Huang H; Qin Y; Han X; Wu D; Song L; Xia Y; Wang X
Environ Toxicol Chem; 2013 Feb; 32(2):353-60. PubMed ID: 23074026
[TBL] [Abstract][Full Text] [Related]
15. Perfluoroalkylated substances (PFAS) affect neither estrogen and androgen receptor activity nor steroidogenesis in human cells in vitro.
Behr AC; Lichtenstein D; Braeuning A; Lampen A; Buhrke T
Toxicol Lett; 2018 Jul; 291():51-60. PubMed ID: 29601859
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the toxicological databases for 6:2 fluorotelomer alcohol (6:2 FTOH) and perfluorohexanoic acid (PFHxA).
Rice PA; Aungst J; Cooper J; Bandele O; Kabadi SV
Food Chem Toxicol; 2020 Apr; 138():111210. PubMed ID: 32087313
[TBL] [Abstract][Full Text] [Related]
17. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
[TBL] [Abstract][Full Text] [Related]
18. Developing scientific confidence in HTS-derived prediction models: lessons learned from an endocrine case study.
Cox LA; Popken D; Marty MS; Rowlands JC; Patlewicz G; Goyak KO; Becker RA
Regul Toxicol Pharmacol; 2014 Aug; 69(3):443-50. PubMed ID: 24845243
[TBL] [Abstract][Full Text] [Related]
19. Elimination kinetics of perfluorohexanoic acid in humans and comparison with mouse, rat and monkey.
Russell MH; Nilsson H; Buck RC
Chemosphere; 2013 Nov; 93(10):2419-25. PubMed ID: 24050716
[TBL] [Abstract][Full Text] [Related]
20. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
